New ASH25 Insights on Bleeding Risk in Cancer-Associated VTE
Marc Carrier, Professor at Ottawa Hospital Research Institute, shared on LinkedIn:
”New Insights on Bleeding Risk During Extended Anticoagulation in Cancer-Associated VTE
Presented at ASH25 and published in Lancet Haematology, this post-hoc analysis of the API-CAT trial, led by Prof. Isabelle Mahé, identifies key predictors of clinically relevant bleeding during extended apixaban therapy in patients with active cancer.
Key Predictors of Higher Bleeding Risk
• Anemia and/or thrombocytopenia (HR 1.93)
• Age ≥75 years (HR 1.51)
• Index pulmonary embolism (HR 1.47)
• Male sex (HR 1.38)
These predictors were consistent across cancer types and also aligned with predictors of major bleeding. See manuscript here.”
Title: Predictors of clinically relevant bleeding during extended anticoagulation for cancer-associated venous thromboembolism (API-CAT): a post-hoc analysis of a randomised, non-inferiority trial
Authors: Prof Isabelle Mahé, Céline Chapelle, Philippe Girard, Marc Carrier, Luis Jara Palomares, Prof Charles-Marc Samama, Hélène Helfer, Prof Grigoris Gerotziafas, Prof Silvy Laporte, Prof Eric Vicaut, Prof Patrick Mismetti
Stay updated with Hemostasis Today.
-
Jan 25, 2026, 15:57Céline Chapelle Shares Clinical Predictors From the API-CAT Trial
-
Jan 25, 2026, 15:42Francesco Lo Monaco on Heart Disease Starting Quiet While Your Labs Speak First
-
Jan 25, 2026, 15:33Wilfried Dinh: Why Heart Patients Still Have Events Despite ”Optimal” Cardiovascular Therapy
-
Jan 25, 2026, 15:25Muhammad Ibrahim on Efficacy and Safety of Extended DOACs Use in VTE
-
Jan 25, 2026, 15:08Tushar Pandey on Managing Thrombotic Thrombocytopenic Purpura
-
Jan 25, 2026, 14:55Carolina Contreras Cuevas Shares a Nationwide Study on VTE in PAD
-
Jan 25, 2026, 14:40Jeannie Devereaux Links PRP and Physical Therapy
-
Jan 25, 2026, 14:25Heghine Khachatryan on Anticoagulation After AFib Ablation: New Evidence from NEJM
-
Jan 25, 2026, 12:42Lale Tokgözoğlu on Cardiovascular Risk Factors in Women